No dividends for the time being while prioritizing R&D, with future dividends under consideration
First written in FY2019. 3 of 4 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2025: 2 of 19 companies on the "Worse" side.
31 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Because we will continue to invest actively in pharmaceutical research and development, we plan not to pay dividends for the time being. At the same time, we recognize returning profits to shareholders as an important management issue and will consider dividends in light of future operating results and financial position.」
研究開発投資を優先して当面無配とし、将来の配当を検討する方針を再確認している。 - FY2022RestatedAnnual report
「Because we will continue to invest actively in pharmaceutical research and development, we plan not to pay dividends for the time being. At the same time, we recognize returning profits to shareholders as an important management issue and will consider dividends in light of future operating results and financial position.」
研究開発投資を優先して当面無配としつつ、将来の利益配当を検討する方針を再確認している。 - FY2021RestatedAnnual report
「Because we will continue to invest actively in pharmaceutical research and development, we plan not to pay dividends for the time being. At the same time, we recognize returning profits to shareholders as an important management issue and will consider dividends in light of future operating results and financial position.」
研究開発投資を優先して当面無配としつつ、将来の利益配当を検討する方針を再確認している。 - FY2019First statedAnnual report
「Because we will continue to invest actively in pharmaceutical research and development, we plan not to pay dividends for the time being. At the same time, we recognize returning profits to shareholders as an important management issue and will consider dividends in light of future operating results and financial position.」
研究開発投資を優先して当面無配とする一方、将来の利益配当を検討する方針を示している。